Literature DB >> 17578348

Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer.

Hoenil Jo1, Sokbom Kang, Jae W Kim, Gyeong H Kang, Noh H Park, Yong S Song, Sang Y Park, Soon B Kang, Hyo P Lee.   

Abstract

AIM: The aim of the present study was to evaluate the DNA hypermethylation profiles of 14 genes known to be associated with tumor behavior and their clinical significance in cervical cancer.
METHOD: The clinical features of 82 patients with stage IB cervical cancer were analyzed in terms of DNA hypermethylation of 14 genes (hMLH1, p16, COX-2, CDH1, APC, DAPK, MGMT, p14, RASSF1A, RUNX3, TIMP3, FHIT, THBS1, and HLTF).
RESULTS: Of 14 genes investigated, only hypermethylation of COX-2 showed significant association with poor disease-free survival (P = 0.001). To further investigate an alteration in COX-2 expression by DNA hypermethylation, immunohistochemistry for COX-2 protein was performed in the cervical cancer tissues. We found no significant association between hypermethylation and expression patterns of the COX-2 gene.
CONCLUSIONS: The present results suggest that DNA hypermethylation of the COX-2 gene may be a potential prognostic marker in early stage cervical cancer, the underlying mechanism of which is independent of gene silencing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578348     DOI: 10.1111/j.1447-0756.2007.00517.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  10 in total

1.  Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity.

Authors:  SungHwan Cho; Senthilkumar Cinghu; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-10       Impact factor: 4.553

Review 2.  The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Authors:  Ludovic Dhont; Céline Mascaux; Alexandra Belayew
Journal:  Cell Mol Life Sci       Date:  2016-01       Impact factor: 9.261

3.  DNA methylation and carcinogenesis of PRDM5 in cervical cancer.

Authors:  Hai-Yan Cheng; Xiu-Wei Chen; Li Cheng; Yun-Duo Liu; Ge Lou
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

4.  Promoter methylation status of the tumor suppressor genes p16 and cadherin 1 in cervical intraepithelial neoplasia.

Authors:  Ruei-Nian Li; Chien-Yu Li; Chien-Hung Lee; Chiung-Yu Peng; Ming-Tsang Wu
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

Review 5.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

6.  DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer.

Authors:  H Y Cheng; Y Gao; Ge Lou
Journal:  Eur J Med Res       Date:  2010-01-29       Impact factor: 2.175

7.  Quantitative DNA methylation analysis of candidate genes in cervical cancer.

Authors:  Erin M Siegel; Bridget M Riggs; Amber L Delmas; Abby Koch; Ardeshir Hakam; Kevin D Brown
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

8.  Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.

Authors:  Jin Huang; Jia-You Luo; Hong-Zhuan Tan
Journal:  PLoS One       Date:  2019-10-01       Impact factor: 3.240

Review 9.  Targeting Lipid Peroxidation for Cancer Treatment.

Authors:  Sofia M Clemente; Oscar H Martínez-Costa; Maria Monsalve; Alejandro K Samhan-Arias
Journal:  Molecules       Date:  2020-11-05       Impact factor: 4.411

10.  A novel miRNA identified in GRSF1 complex drives the metastasis via the PIK3R3/AKT/NF-κB and TIMP3/MMP9 pathways in cervical cancer cells.

Authors:  Qi Sun; Zhen Yang; Pu Li; Xu Wang; Lu Sun; Shixing Wang; Min Liu; Hua Tang
Journal:  Cell Death Dis       Date:  2019-09-02       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.